Enlivex Therapeutics (NASDAQ:ENLV) Announces Earnings Results, Beats Expectations By $12.88 EPS

Enlivex Therapeutics (NASDAQ:ENLV) released its earnings results on Wednesday. The company reported $12.85 earnings per share for the quarter, topping the consensus estimate of ($0.03) by $12.88, FiscalAI reports.

Enlivex Therapeutics Stock Down 0.9%

Enlivex Therapeutics stock opened at $1.10 on Wednesday. The firm has a market cap of $261.12 million, a price-to-earnings ratio of -2.00 and a beta of 1.55. Enlivex Therapeutics has a 52 week low of $0.66 and a 52 week high of $2.10. The business’s 50-day moving average price is $1.09 and its 200 day moving average price is $1.02.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Virtu Financial LLC purchased a new stake in Enlivex Therapeutics in the 4th quarter worth approximately $33,000. Invesco Ltd. purchased a new position in shares of Enlivex Therapeutics during the 4th quarter valued at approximately $43,000. XTX Topco Ltd increased its holdings in shares of Enlivex Therapeutics by 44.8% during the 4th quarter. XTX Topco Ltd now owns 61,800 shares of the company’s stock valued at $43,000 after purchasing an additional 19,132 shares in the last quarter. Jane Street Group LLC lifted its stake in shares of Enlivex Therapeutics by 244.1% in the 4th quarter. Jane Street Group LLC now owns 74,082 shares of the company’s stock valued at $52,000 after purchasing an additional 52,553 shares during the period. Finally, Susquehanna International Group LLP acquired a new position in shares of Enlivex Therapeutics in the 3rd quarter valued at $57,000. 1.02% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have issued reports on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enlivex Therapeutics in a report on Monday, December 29th. HC Wainwright boosted their price objective on shares of Enlivex Therapeutics from $7.00 to $13.00 and gave the company a “buy” rating in a report on Monday, January 12th. Finally, Wall Street Zen raised Enlivex Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $13.00.

About Enlivex Therapeutics

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.